APA (7th ed.) Citation

Braunlin, E., Rosenfeld, H., Kampmann, C., Johnson, J., Beck, M., Giugliani, R., . . . Harmatz, P. (2013). Enzyme replacement therapy for mucopolysaccharidosis VI: Long-term cardiac effects of galsulfase (Naglazyme®) therapy. Journal of inherited metabolic disease, 36(2), 385-394. https://doi.org/10.1007/s10545-012-9481-2

Chicago Style (17th ed.) Citation

Braunlin, E., et al. "Enzyme Replacement Therapy for Mucopolysaccharidosis VI: Long-term Cardiac Effects of Galsulfase (Naglazyme®) Therapy." Journal of Inherited Metabolic Disease 36, no. 2 (2013): 385-394. https://doi.org/10.1007/s10545-012-9481-2.

MLA (9th ed.) Citation

Braunlin, E., et al. "Enzyme Replacement Therapy for Mucopolysaccharidosis VI: Long-term Cardiac Effects of Galsulfase (Naglazyme®) Therapy." Journal of Inherited Metabolic Disease, vol. 36, no. 2, 2013, pp. 385-394, https://doi.org/10.1007/s10545-012-9481-2.